Skip to main content
. 2010 Jan 25;54(4):1443–1452. doi: 10.1128/AAC.01022-09

FIG. 4.

FIG. 4.

Linezolid twice-daily 0.5-h infusion of 200 or 600 mg over 48 h against E. faecalis Ef1497MutM3. Shown are the pharmacokinetic and pharmacodynamic effects of linezolid on E. faecalis Ef1497MutM3 during the simulation of twice-daily 0.5-h infusion of 200 mg (A1) and 600 mg (B1) over 48 h in the in vitro PK-PD model (mean; n = 2). ⧫, PCp concentration-time curve; ▴, control growth curve; ▪, killing and regrowth curve. (A2 and B2) Emergence of linezolid-resistant mutants of Ef1497MutM3 during the corresponding simulations (mean percentage of viable counts; n = 2). Blue, control; red, resistant to 8.0 μg/ml; orange, resistant to 16 μg/ml.